Maurie Markman, MD


PFS Deserves More Than Surrogate Status as a Clinical Trial End Point

January 20th 2021

Although recent benefits do not pertain to all cancers and “cure” remains a relatively uncommon event, oncologists have an increasing number of molecularly targeted and immunotherapeutic strategies to employ based on objectively meaningful clinical trial outcomes.

Dr. Markman on Remaining Questions With HPV- Cervical Cancer

January 18th 2021

Maurie Markman, MD, discusses remaining questions regarding human papillomavirus–negative cervical cancer.

Markman: COVID-19 Takes Science on a Roller-Coaster Ride

January 10th 2021

In a pandemic, the public and its leaders yearn for relatively simple answers that can lead to solutions and forceful actions such as preventing serious infection and hospitalizations, treating active illness, and developing safe and effective vaccines quickly made available to the public.

Real-World Impact of Low-Grade AEs Needs a Closer Look

November 18th 2020

Although PARP inhibitors are generally reasonably well tolerated, certainly compared with platinum and other routinely employed cytotoxic antineoplastic drugs, the majority of patients receiving PARP inhibitors in multiple reported clinical trials reported low-grade nausea and fatigue.

Dr. Markman on the Benefit of PARP Inhibitors in Ovarian Cancer

November 6th 2020

Maurie Markman, MD, discusses the utility of PARP inhibitors in ovarian cancer.

HPV Vaccination Is a Battle That Must Be Won

November 2nd 2020

Despite solid evidence that human papillomavirus vaccination is remarkably effective in preventing persistent infection by HPV types that are known to be responsible for more than 70% to 80% of cervical cancer cases worldwide, this strategy’s utility in substantially reducing the subsequent development of the malignancy itself remained an open question.

Complex Clinical Trial Issues Require an Ethical Balancing Act

October 13th 2020

The fundamental objectivity of major scientifically oriented public health agencies has been called into question, while the issue of what constitutes sufficient evidence for a therapeutic strategy to be considered “standard” is also being challenged.

Technological Advances Come With a Cautionary Note

September 30th 2020

In the realm of medicine, we see enormous opportunities for truly novel technologies to revolutionize the health and welfare of all members of society.

Scramble Over COVID-19 Clinical Trials Holds Lessons for Oncology

September 12th 2020

Because it is likely that COVID-19 will be around for a considerable period of time, it is hoped that all involved in the clinical research establishment can view this experience as a process that needs substantial improvement.

It’s Time to Modernize Genetic Counseling in Oncology

August 14th 2020

Several developments emphasize the increasing clinical relevance of germline testing within the oncology arena and the need for associated genetic counseling.